Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000911176 | SCV001056234 | benign | not provided | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003169284 | SCV003869830 | uncertain significance | Inborn genetic diseases | 2023-01-31 | criteria provided, single submitter | clinical testing | The c.1361C>A (p.A454D) alteration is located in exon 9 (coding exon 9) of the FN1 gene. This alteration results from a C to A substitution at nucleotide position 1361, causing the alanine (A) at amino acid position 454 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV000911176 | SCV004183865 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000911176 | SCV005243906 | benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004746152 | SCV005353384 | likely benign | FN1-related disorder | 2024-08-02 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |